CAR-T treatment moves earlier as FDA widens approval of Gilead’s Yescarta

There are some obstacles to use. Yescarta is expensive, priced by Gilead at $373,000 per patient. Treatment is now widely covered by insurance, but the cost can still present hurdles for patients, depending on their coverage plans.